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SYSTEMATIC REVIEW OF COMBINATION 
ANTIRETROVIRAL THERAPY WITH DIDANOSINE 
PLUS HYDROXYUREA: A PARTIAL SOLUTION TO 
AFRICA’S HIV/AIDS PROBLEM? 
We do not agree with the conclusion of Sanne and col- 
leagues that didanosine and hydroxyurea is a safe, 
effective, and economically relevant alternative to exist- 
ing antiretroviral regimens for poor-resource patient 
populations. l 
So far randomized clinical trials have not been able 
to demonstrate a clear benefit from hydroxyurea- 
containing regimens. Hydroxyurea reduces the viral 
load, but it is unclear whether this parameter is a good 
surrogate marker for evaluating the efficacy of this drug. 
Hydroxyurea may be harmful because it is cytostatic 
and reduces the CD4+ lymphocyte count2 Moreover, it 
increases the toxicity of didanosine, leading to a higher 
incidence of peripheral neuropathy and pancreatitis3z4 
It certainly should not be used in pregnant women or 
women at risk of becoming pregnant. One randomized 
trial (the AIDS Clinical Trial Group [ACTG] 65025 study) 
was prematurely stopped because of high rates of drug 
toxicity in the hydroxyurea arm. Among 68 patients ran- 
domized to the hydroxyurea arm, three deaths related 
to complications of pancreatitis were reported.5 For 
these reasons we believe it is premature to recommend 
the use of hydroxyurea in daily clinical practice, even 
in countries with poor resources. However, we agree 
that additional randomized trials using hydroxyurea are 
needed to define the potential role of this drug in the 
treatment of human immunodeficiency virus (HIV). Such 
trials should include a sufficiently large number of par- 
ticipants who are followed for long enough to detect a 
significant difference in clinical outcome. Recently the 
prices of antiretrovirals have dropped sharply, and highly 
active antiretroviral treatment (HAART) regimens have 
been offered at U.S. $1 to $2 a day.’ Such treatment reg- 
imens are known to be highly efficacious; therefore, 
new alternative treatment strategies should be com- 
pared with classic HAART regimens in clinical trials 
before proposing their use on the basis of economic 
arguments alone. 
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RESPONSE 
In the context of human immunodeficiency virus (HIV) 
infection, some treatment is better than no treatment. 
Whereas we agree with some points raised by Colebun- 
ders and colleagues regarding the use of didanosine (ddI)- 
hydroxyurea for HIV infection, we believe that in poor 
countries of the world this drug combination has pro- 
vided, and continues to offer a useful alternative to other 
antiretroviral regimens. In several independent studies 
hydroxyurea has been shown to inhibit HIV-l DNA syn- 
thesis in infected quiescent and activated primary human 
lymphocytes and macrophages, by stimulating the 
immune system and increasing the percentage of naive 
cells and the percentage of cells capable of responding 
to antigen.’ In combination with a reverse transcriptase 
inhibitor with or without a protease inhibitor, HIV sup- 
pression may occur as efficiently as with standard highly 
active antiretroviral therapies (HAART). In addition to its 
consistent short-term reduction on HIV-l RNA levels, the 
long-term safety and antiretroviral activity of ddI-hydrox- 
yurea have been documented for periods up to 25 
months without evidence of viral rebound.2 Didanosine- 
resistant HIV-l mutants retain sensitivity to dd1 in the 
presence of hydroxyurea. Furthermore, by exerting a 
cytostatic effect on CD4+ and CD8+ T lymphocytes, 
hydroxyurea may actually reduce HIV-l replication by 
decreasing CD4+ T-cell proliferation and preventing the 
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exhaustion of CDS+ T-cell populations that may occur as 
a result of excessive activation in the context of HIV-l 
infection.3 
As the authors comment, the addition of hydroxy- 
urea to didanosine may increase the incidence of side 
effects, such as peripheral neuropathy and pancreatitis, 
compared to ddI alone (in general, additive adverse effects 
may occur when using combination chemotherapy for 
HIV tuberculosis, etc.). However, this should not be a con- 
traindication to the use of this efficacious drug combi- 
nation in areas where financial resources and therapeutic 
options remain limited. An unfortunate editorial mishap 
caused our original manuscript to be delayed more than 
2 l/2 years from submission to publication in this Jour- 
nal. Admittedly, the political and economic climates for 
HAART have changed dramatically in certain developing 
countries since we conducted our meta-analysis and for- 
mulated our conclusion as to the potential role of ddI- 
hydroxyurea, thus making some other regimens relatively 
more affordable today. However, until more active anti- 
retroviral drug regimens become more universally acces- 
sible, we believe that the combination of ddI-hydroxyurea 
remains a relevant and beneficial option. 
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